Jack Gallagher
Jack Gallagher (Educ ’68)
Jack Ray Gallagher (Educ ’68) has been appointed editor of Current Trends in Clinical and Medical Sciences. He also co-chaired the session on gynecological oncology at the PCS Fourth Global Obstetrics and Gynaecology 2019 Congress where he spoke about his real-world observational studies and artificial intelligence enhancements. His presentation at the European Society for Medical Oncologists Congress 2018 on adverse events of a PARP inhibitor, a new type of ovarian cancer treatment, was selected by OncLive for publication and distribution to oncologists around the world. He currently directs Clarity Pharma Research, a scientific research organization.
Jack Gallagher (Educ ’68)
Jack R. Gallagher, Ed.D., M.Sc. (Educ ’68) published results of national studies of pulmonary non-tuberculosis mycobacteria (PNTM) that he directed in France, Germany, Italy, Spain and UK. PNTM is a rare disease that can be fatal if untreated. Findings appeared in the December issue of European Respiratory Journal. During the past five years, Mr. Gallagher also directed national studies of PNTM in Japan, Canada and the US, resulting in 16 additional journal articles and conference papers/presentations in such venues as Annals of the American Thoracic Society, American Journal of Respiratory and Critical Care Medicine, Value in Health, 2015 and 2016 International Society for Pharmacoeconomics and Outcomes Research (Milan and Vienna), 2015 Congress on Infectious Disease and Tropical Medicine (Cologne), and 2015 Japan Respiratory Society Annual Meeting (Tokyo). The scientific reach of his 78 publications is greater than 87% of the 12+ million Research Gate scientists (https://www.researchgate.net/profile/Jack_Gallagher2). He completed his clinical psychology internship at Lynchburg Training School and Hospital in Lynchburg, Va., and formerly served on the faculties of UVA’s Schools of Education and Medicine. He is founder and chief scientist of Clarity Pharmaceutical Research, LLC, a global medical research firm headquartered in Spartanburg, S.C.
Jack Gallagher (Educ ’68)
Jack Gallagher (Educ ’68), a former faculty member in the Curry School of Education and the School of Medicine, has published findings from studies that he directed in the U.S. and Europe on non-muscle invasive bladder cancer. He co-authored two papers on his research, “The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries,” which appears in the August 2013 issue of World Journal of Urology; and “National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer,” published in the May 2012 issue of the Journal of Urology. Mr. Gallagher currently serves as president of Clarity Pharma Research.